

Consolidated Financial Results for the Six Months Ended June 30, 2025
(Under Japanese GAAP)

August 5, 2025

Company name	CREATE MEDIC CO., LTD.		
Stock exchange listings	: Tokyo Standard		
Securities code	5187		
URL	https://www.createmedic.co.jp/english/		
Representative	Osamu Imazawa	President	
Inquiries	Teruya Ueno	Executive Officer, General Manager of Accounting Department	
Semi-annual statement filing date (as planned)	: August 8, 2025		
Dividend payable date (as planned)	: September 8, 2025		
Supplemental material of results	: Yes		
Convening briefing of results	: Yes, only in Japanese (For individual investors and institutional investors)		

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended June 30, 2025 (from January 1, 2025 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	6,564	4.2	548	88.3	525	51.8	412	(25.0)
June 30, 2024	6,300	4.6	291	(13.3)	345	(6.8)	550	73.9

Note:	Comprehensive income	For the six months ended June 30, 2025 : (157) Millions of yen (—%)
		For the six months ended June 30, 2024 : 1,411 Millions of yen (104.1%)

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
June 30, 2025	48.35	—
June 30, 2024	61.35	—

(2) Consolidated financial position

	Total assets	Net assets	Capital adequacy ratio	Net assets per share
As of	Millions of yen	Millions of yen	%	Yen
June 30, 2025	18,233	15,308	84.0	1,807.51
December 31, 2024	20,047	15,750	78.6	1,833.67

Reference: Owner's equity	As of June 30, 2025	15,308 Millions of yen
	As of December 31, 2024	15,750 Millions of yen

2. Cash dividends

	Annual dividend				
	First quarter	Second quarter	Third quarter	Year end	Annual
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2024	—	19.00	—	20.00	39.00
Fiscal year ending December 31, 2025	—	17.00			
Fiscal year ending December 31, 2025 (Forecast)			—	20.00	37.00

Note: Revisions to the forecast of cash dividends most recently announced : None

3. Consolidated financial forecast for the fiscal year ending December 31, 2025 (from January 1, 2025 to December 31, 2025)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
Fiscal year ending	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
December 31, 2025	13,583	4.2	1,002	44.7	1,043	39.0	796	(5.3)	92.67

Note: Revisions to the earnings forecasts most recently announced : None

* Notes

(1) Significant changes in the scope of consolidation during the period : None

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies due to other reasons : None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(4) Number of issued shares (common shares)

① Number of issued and outstanding shares at the period end (including treasury stock)

As of June 30, 2025	9,664,327shares	As of December 31, 2024	9,664,327shares
As of June 30, 2025	1,195,116shares	As of December 31, 2024	1,074,624shares
Six months ended June 30, 2025	8,539,299shares	Six months ended June 30, 2024	8,972,194shares

② Number of treasury stock at the period end

③ Average number of shares

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Caution Regarding Forward-Looking Statements:

The forward-looking statements contained in this document are based on information currently available to the Company and certain assumptions that the Company deems to be reasonable. They are not intended as a promise by the Company that they will be achieved, and actual results may differ significantly due to various factors.